Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis

Table 3 Influence of baseline characteristics on duration of time to treatment based on univariate analyses

Patient variable	Time to treatment (h)	p (univariate)
Age (years)		0.15
<65	22.6 ± 12.3
65 – 74	22.3 ± 11.9
≥75	22.0 ± 11.4
Sex		0.08
Male	22.7 ± 12.1
Female	22.0 ± 11.9
APACHE II score		< 0.0001
First quartile (3 – 17)	23.9 ± 13.4
Second quartile (18 – 22)	22.9 ± 12.5
Third quartile (23 – 28)	21.9 ± 11.2
Fourth quartile (29 – 53)	20.9 ± 10.7
Number of organ dysfunctions		< 0.0001
1	19.0 ± 12.2
2	21.7 ± 11.8
3	23.6 ± 11.7
4	23.9 ± 11.5
5	27.0 ± 12.7
On a ventilator		< 0.0001
Yes	23.5 ± 12.0
No	18.1 ± 10.9
On vasopressors		< 0.0001
Yes	23.3 ± 11.7
No	20.9 ± 12.8
Recent surgery		< 0.0001
Yes	24.4 ± 11.8
No	21.3 ± 12.0
Unknown	24.4 ± 13.2

Results are means ± SD. APACHE, Acute Physiology and Chronic Health Evaluation score. Statistics are based on one-way analysis of variance.

ISSN: 1364-8535